Brief: Biohit H2 Operative EBITDA Down At EUR 0.0 Million

Biohit Oyj

20/02/2019 07:33

Feb 20 (Reuters) - Biohit Oyj  BIOBV.HE :
    * H2 NET SALES EUR 5.0 MILLION VERSUS EUR 4.9 MILLION YEAR
AGO
    * SAYS WE EXPECT GROWTH TO CONTINUE DURING 2019 DESPITE OF
DELAY
IN CHINA RE-REGISTRATION PROCESS REGARDING GASTROPANEL
    * DURING H2/2018 OUR GROWTH WAS ONLY 2% DUE TO A DELAY IN
RE-REGISTRATION OF ONE OF OUR GASTROPANEL PRODUCTS IN CHINA
    * WE EXPECT TO GET REGISTRATION COMPLETED BY END OF H1/2019
    * H2 OPERATIVE EBITDA EUR 0.0 MILLION (EUR 0.3 MILLION)
    * BIOHIT'S DISTRIBUTOR BIOHIT HEALTHCARE (HEFEI) ANNOUNCED
IT WILL
MAKE SIGNIFICANT INVESTMENT TO EXPAND ITS PRODUCTION CAPACITY
    * ACCORDING LATEST ESTIMATE NEW CAPACITY WILL BE AVAILABLE
UNTIL
END OF Q1/2020.
    * GASTROPANEL MARKET SITUATION IN CHINA IS STRONG AND WE
EXPECT
DEMAND TO GROW IN COMING YEARS.
    * "BIOHIT EXPECTS ITS 2019 NET SALES GROWING COMPARING 2018
(PREVIOUS YEAR EUR 9.9 MILLION)."
    * BOARD OF DIRECTORS PROPOSES TO ANNUAL GENERAL MEETING THAT
NO
DIVIDEND BE PAID FOR FISCAL YEAR.

Source text for Eikon:  ID:nGNE8nVYfS 
Further company coverage:  BIOBV.HE 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))